Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

Keith L. Knutson, Matthew S. Block, Nadine Norton, Courtney L. Erskine, Timothy J. Hobday, Allan B. Dietz, Douglas Padley, Michael P. Gustafson, Danell Puglisi-Knutson, Toni Kay Mangskau, Saranya Chumsri, Amylou C. Dueck, Lavakumar Karyampudi, Glynn Wilson, Amy C. Degnim

Clin Cancer Res (2020) 26 (5): 1045–1053.

https://doi.org/10.1158/1078-0432.CCR-19-2123

Published: 02 March 2020

View articletitled, Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

Journal Articles

Intratumoral CD14⁺ Cells and Circulating CD14⁺HLA-DR^lo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

Michael P. Gustafson, Yi Lin, Jonathan S. Bleeker, Deepti Warad, Matthew K. Tollefson, Paul L. Crispen, Peggy A. Bulur, Susan M. Harrington, Rebecca R. Laborde, Dennis A. Gastineau, Bradley C. Leibovich, John C. Cheville, Eugene D. Kwon, Allan B. Dietz

Clin Cancer Res (2015) 21 (18): 4224–4233.

https://doi.org/10.1158/1078-0432.CCR-15-0260

Published: 14 September 2015

View articletitled, Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

Includes: Supplementary data

Journal Articles

Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study

Kimberly R. Kalli, Courtney L. Erskine, James W. Krempski, Linda M. Benson, Vera J. Suman, Douglas J. Padley, Allan B. Dietz, Timothy J. Hobday, Amy C. Degnim, Lynn C. Hartmann, Matthew S. Block, Keith L. Knutson

Clin Cancer Res (2013) 19 (19_Supplement): A82.

https://doi.org/10.1158/1078-0432.OVCA13-A82

Published: 13 May 2014

View articletitled, Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study

Journal Articles

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Jann N. Sarkaria, Eva Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, Laurence Doyle, Caterina Giannini, Kurt A. Jaeckle, Jan C. Buckner

Clin Cancer Res (2010) 16 (22): 5573–5580.

https://doi.org/10.1158/1078-0432.CCR-10-1453

Published: 14 November 2010

View articletitled, Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Journal Articles

Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

Emily K. Mader, Yoshihiro Maeyama, Yi Lin, Greg W. Butler, Holly M. Russell, Evanthia Galanis, Stephen J. Russell, Allan B. Dietz, Kah-Whye Peng

Clin Cancer Res (2009) 15 (23): 7246–7255.

https://doi.org/10.1158/1078-0432.CCR-09-1292

Published: 30 November 2009

View articletitled, Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

Intratumoral CD14⁺ Cells and Circulating CD14⁺HLA-DR^lo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

Email alerts

AACR Journals

Update search

Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine

Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

Abstract A82: Metronomic cyclophosphamide followed by a multi-peptide folate receptor vaccine for ovarian and breast cancer immunotherapy in the setting of minimal residual disease - a feasibility study

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Intratumoral CD14⁺ Cells and Circulating CD14⁺HLA-DR^lo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma